BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Angelousi A, Koumarianou A, Chatzellis E, Kaltsas G. Resistance of neuroendocrine tumours to somatostatin analogs. Expert Rev Endocrinol Metab 2023;18:33-52. [PMID: 36651768 DOI: 10.1080/17446651.2023.2166488] [Reference Citation Analysis]
2 Panzuto F, Ricci C, Rinzivillo M, Magi L, Marasco M, Lamberti G, Casadei R, Campana D. The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Clin Med 2022;11. [PMID: 36294448 DOI: 10.3390/jcm11206127] [Reference Citation Analysis]
3 Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol 2022. [PMID: 35501552 DOI: 10.1007/s11864-022-00983-z] [Reference Citation Analysis]
4 Stankiewicz R, Grąt M. Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(4): 276-285 [DOI: 10.4240/wjgs.v14.i4.276] [Reference Citation Analysis]
5 Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer 2021;157:403-14. [PMID: 34597974 DOI: 10.1016/j.ejca.2021.06.056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
6 Cella D, Evans J, Feuilly M, Neggers S, Van Genechten D, Herman J, Khan MS. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. Adv Ther 2021;38:969-93. [PMID: 33432541 DOI: 10.1007/s12325-020-01600-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Alvarez MA, Anderson K, Deneve JL, Dickson PV, Yakoub D, Fleming MD, Chinthala LK, Zareie P, Davis RL, Shibata D, Glazer ES. Traveling for Pancreatic Cancer Care Is Worth the Trip. Am Surg 2021;87:549-56. [PMID: 33108886 DOI: 10.1177/0003134820951484] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep. 2019;21:13. [PMID: 30868284 DOI: 10.1007/s11894-019-0684-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]